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Purpose:  The aim of this study was to investigate the expression pattern of cal-
cium-binding proteins S100A2 and S100A4. We also sought to determine the prognostic 
value of these markers for patients with prostate adenocarcinoma.
Materials and Methods: Immunohistochemical staining was performed to detect 
S100A2 and S100A4 expression in 26 tissue samples obtained during transurethral 
resection from patients with benign prostatic hyperplasia (BPH) and in 67 tissue sam-
ples obtained during prostate biopsy and radical prostatectomy from patients with 
prostate carcinoma. The immunoreactivity of these proteins was stratified on a scale 
of 0 to 3 and was correlated with the pathologic features of prostate adenocarcinoma.
Results: High expression of S100A2 was observed in the tissue of patients with BPH, 
whereas low or no expression was observed in prostate cancer (CaP) cells. The protein 
level of S100A4 was significantly higher in CaP than in BPH cells. The higher level 
of S100A4 observed in CaP tissue correlated with increasing tumor grade.
Conclusions: Decreased expression of S100A2 and increased expression of S100A4 may 
be important in the progression of CaP. This finding could aid in identifying aggressive 
CaP. The simultaneous analysis of S100A2 and S100A4 expression in prostate tissues 
may be a useful prognostic marker for CaP.
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INTRODUCTION
Prostate cancer (CaP) has the highest incidence among 
cancers in the US and is the second leading cause of can-
cer-associated death in men [1]. In Korea, its incidence is 
still increasing, compared to that of other cancers and it 
ranked fifth in incidence in 2005 [2]. Despite recent im-
provements in diagnosis and therapeutic techniques, the 
survival rate of CaP patients is poor because of the re-
currence of the disease [1,3]. The lack of effective therapies 
for advanced CaP is related to a large extent to poor under-
standing of the molecular mechanisms underlying the pro-
gression of this disease (invasion and metastasis) [4]. 
Identification of predictive markers for CaP, especially 
those that are indicative of the invasiveness of the disease, 
is important for improving clinical management, out-
comes, and survival of these patients. The S100 cal-
cium-binding proteins have recently attracted consid-
erable interest because of their differential expression in 
neoplastic and normal tissues, and their involvement in 
metastatic processes [5,6]. S100 proteins are involved in a 
variety of intracellular and extracellular functions includ-
ing cell growth, cell-to-cell communication, energy metab-
olism, and intracellular signal transduction [6,7]. 
  S100A2 is tumor-suppressor gene that is typically down-
regulated in cells that have acquired a tumorigenic pheno-
type, which suggests that S100A2 has an important role in 
inhibiting cancer progression [8]. Differential expression 
of S100A2 has been reported in breast cancer, melanoma, 
and other types of cancer [9-14]. Korean J Urol 2010;51:456-462
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FIG. 1. Grading system used for in the expression of S100A2 (H&E, x100). The degree of expression was graded on 4-point scale of 0
to 3: 0 (negative stain), 1＋(weak staining), 2＋(moderate staining), and 3＋(strong staining). (A) Strong cytoplasmic expression of 
S100A2 was observed in benign prostatic hyperplasia tissue. (B)  Moderate cytoplasmic expression of S100A2 was observed in CaP
tissue (Gleason score 6). (C) There was weak cytoplasmic expression of S100A2 in CaP tissue (Gleason score 7). (D) Negative 
cytoplasmic expression of S100A2 in the CaP tissue (Gleason score 8). CaP: prostate cancer.
  S100A4, another member of the S100 protein family, is 
associated with the invasion and metastasis of malignant 
tumors [15]. S100A4 is frequently overexpressed in meta-
static tumors, as well as in normal cells with uninhibited 
movement, such as macrophages, neutrophils, and T-lym-
phocytes [16]. It is also overexpressed in various cancer 
types such as those of the breast, ovary, and colon [6,17,18]. 
　  In this study, we aimed to determine the expression pat-
tern of S100A2 and S100A4 and to assess the prognostic 
value of these markers in patients with prostate adeno-
carcinoma. 
MATERIALS AND METHODS
1. Selection of patients and tissues 
Immunohistochemical staining for S100A2 and S100A4 
was performed on 26 tissue samples obtained during tran-
surethral resection from patients with benign prostatic hy-
perplasia (BPH) and 67 tissue samples obtained during 
prostate biopsy (n=7) and radical prostatectomy (n=60) 
from patients with prostate carcinoma. We divided the CaP 
tissue samples (n=67) into 3 groups based on their Gleason 
grade: Gleason grade 6 or lower (low grade) (n=24, 35.8%), 
Gleason grade 7 (intermediate grade) (n=24, 35.8%), and 
Gleason grade 8 or higher (high grade) (n=19, 28.4%). The 
samples were also assigned to one of three groups based on 
clinical stage: localized CaP (n=36, 53.7%), locally ad-
vanced CaP (n=13, 19.4%), and metastatic CaP (n=18, 
26.9%). 
2. Immunohistochemistry 
Formalin-fixed, paraffin-embedded, 5 μm-thick sections 
were dewaxed in xylene, rehydrated in graded solutions of 
alcohol, and placed in an endogenous peroxide-blocking 
solution for 15 min. Sections were placed in a citrate buffer 
(10% citrate buffer stock in distilled water, pH 6.0). Korean J Urol 2010;51:456-462
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FIG. 2. Immunostaining of S100A4 protein in representative samples from cancer tissue with different degrees of progression of 
prostate cancer (CaP) (H&E, x100). (A) The cytoplasmic expression of S100A4 in benign prostatic hyperplasia tissue was negative. 
(B) Weak in CaP tissue (Gleason score 6). (C) Moderate in CaP tissue (Gleason score 7). (D) There was strong cytoplasmic expression
of S100A4 in CaP tissue (Gleason score 8). CaP: prostate cancer.
Nonreactive staining was blocked by incubation with 1% 
horse serum in Tris-buffered saline (pH 6.0) for 3 min. The 
primary antibodies for S100A2 (R&D Systems, Inc., 
Minneapolis, MN, USA) and S100A4 (Thermo Scientific, 
Waltham, MA, USA) were incubated with the sections 
overnight. Antibody-binding was detected by use of a 
standard labeled streptavidin-biotin system (Life Science 
Division, Mukilteo, USA). Breast cancer tissue was used 
as an external positive control. For negative controls, the 
primary antibodies were omitted. 
3. Evaluation of S100 immunostaining 
Positive staining in the cytoplasm of tumor cells was de-
fined as reddish-brown staining in at least 10% of the tumor 
cells in a section. A semiquantitative scale of 0 to 3 was used 
to score the reactivity the samples. The immunoreactive 
score was determined by the percentage of positive cells 
and the staining intensity, ranging from no detectable sig-
nal (0) to a strong signal seen at lower-power magnification 
(3). Each image was scored as 0 (0%, negative), 1 (10-30%, 
weak), 2 (30-70%, moderate), or 3 (70-100%, strong) and 
classified as low expression (score 0 and 1) and high ex-
pression (score 2 and 3) (Fig. 1, 2). 
4. Statistical analyses 
We examined the difference in S100A2 and S100A4 ex-
pression between BPH and CaP samples among the 
groups, which were classified based on localization of CaP. 
Biochemical progression-free survival was determined 
based on levels of prostate-specific antigen (PSA) and stud-
ied by use of the Kaplan-Meier product limit analysis. 
Differences between the groups were examined by use of 
the log-rank test. Biochemical recurrence was defined as 
an increase of 0.2 ng/ml. Comparisons of means within 
groups were made using the one-way ANOVA test. 
Comparisons of immunostaining scores within groups 
were made using the Kruskall-Wallis test. Sample correla-
tions were estimated using Spearman’s rank correlation. Korean J Urol 2010;51:456-462
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S100A2 expression
No. (%) ρ
b p-value
S100A4 expression
No. (%) ρ
b p-value
01 ＋ 2＋ 3＋ 01 ＋ 2＋ 3＋
BPH
 (n=26)
1 (3.8)  7 (26.9) 15 (57.7)  3 (11.5)
−0.43 ＜0.001
a
18 (69.8)   8 (30.8)    0 (0)   0 (0)
0.73 ＜0.001
a
CaP
 (n=67)
17 (25.4) 32 (47.8) 18 (26.9)   0 (0)   0 (0) 26 (38.8) 28 (41.8) 13 (19.4)
BPH: benign prostatic hyperplasia, CaP: prostate cancer, 
a: Kruskall-Wallis test, 
b: Spearman’s rank correlation
TABLE 2. Expression of S100A2 and S100A4 in BPH and prostate cancer 
S100A2 expression
No. (%) ρ
b p-value
S100A4 expression
No. (%) ρ
b p-value
01 ＋ 2＋ 3＋  0  1 ＋ 2＋ 3＋
LoCaP
 (n=36)
  2 (5.6) 19 (52.8) 15 (41.7) 0 (0)
−0.55 ＜0.001
a
0 (0) 21 (58.3) 12 (33.3)   3 (8.3)
0.45 ＜0.001
a LACaP
 (n=13)
  4 (30.8)   7 (53.8)   2 (15.4) 0 (0) 0 (0)   3 (23.1)   8 (61.5) 2 (15.4)
MetCaP
 (n=18)
11 (61.1)   6 (33.3) 1 (5.6) 0 (0) 0 (0)   2 (11.1)   8 (44.4) 8 (44.4)
LoCaP: localized prostate cancer, LACaP: locally advanced prostate cancer, MetCaP: metastatic prostate cancer, 
a: Kruskall-Wallis 
test, 
b: Spearman’s rank correlation
TABLE 3. Expression of S100A2 and S100A4 in each group based on prostate cancer progression
Mean age±SD (years) p-value
a PSA (ng/ml) p-value
a Follow up period
(months)
p-value
a
BPH 68.28±8.05 0.82
CaP 68.69±8.26
LoCaP (n=36) 66.08±8.42
0.07
10.56±5.68 34.86±10.51
0.12 LACaP (n=13) 68.69±7.55   46.67±10.26 0.02 30.46±10.99
MetCaP (n=18) 72.38±6.07   345.48±710.68 28.72±10.97
Gleason score
  ≤6 (n=24) 67.08±8.18
0.54
 11.61±10.82 33.75±11.11
0.29   7 (n=24) 68.65±8.13  100.30±210.22 0.26 33.63±10.86
  ≥8 (n=19) 71.20±7.16  163.52±374.94 29.00±10.60
PSA: prostate specific antigen, BPH: benign prostatic hyperplasia, CaP: prostate cancer, LoCaP: localized prostate cancer, LACaP: 
locally advanced prostate cancer, MetCaP: metastatic prostate cancer, G/S: Gleason score, 
a: one-way ANOVA test
TABLE 1. Characteristics of patients
Statistical significance was defined as ＜0.05. All analyses 
were performed using the Statistical Package for Social 
Sciences (SPSS), version 12.0 for Windows. 
RESULTS
1. Comparison of S100A2 and S100A4 expression in BPH 
and CaP 
The age of the patient did not differ significantly between 
patients with BPH (68.28±8.05 years) and CaP (68.69± 
8.26 years) (p=0.082) (Table 1). We examined the ex-
pression of S100A2 and S100A4 in benign and cancer 
tissues. We observed that the expression of S100A4 was 
significantly higher than that of S100A2 in CaP tissues (p
＜0.05) (Table 2). In BPH tissues, the expression of S100A2 
was higher than that of S100A4 (p＜0.05) (Table 2). 
2. Association between S100A2 and S100A4 expression 
and clinical stage and pathologic grade (Gleason score)
The age and follow up periods of patients did not differ sig-
nificantly among the groups of CaP patients (p＞0.05). We 
observed that the PSA level of patients was significantly 
different among groups according to clinical stage (p= 
0.023), but not significantly different among groups ac-
cording to pathologic grade (p=0.264) (Table 1).
　A significant progressive increase in S100A4 expression Korean J Urol 2010;51:456-462
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S100A2 expression
No. (%) ρ
b p-value
S100A4 expression
No. (%) ρ
b p-value
01 ＋ 2＋ 3＋ 01 ＋ 2＋ 3＋
G/S≤6
 (n=24)
  0 (0)   9 (37.5) 15 (62.5) 0 (0)
−0.75 ＜0.001
a
0 (0) 21 (87.5)   3 (12.5)    0 (0)
0.83 ＜0.001
a G/S=7
 (n=24)
 3 (12.5) 18 (75.0)   3 (12.5) 0 (0) 0 (0) 2 (8.3) 20 (83.3) 2 (8.3)
G/S ≥8
 (n=19)
14 (73.7)  5 (26.3)    0 (0) 0 (0) 0 (0)    0 (0)   8 (42.1) 11 (57.9)
G/S: Gleason score, 
a: Kruskall-Wallis test, 
b: Spearman’s rank correlation
TABLE 4. Expression of S100A2 and S100A4 in each group based on pathologic grade (Gleason score)
FIG. 3. Kaplan-Meier product-limit analysis of the length of bio-
chemical relapse-free survival among CaP patients with low 
expression (IS=0 or 1) and high expression (IS=2 or 3) of S100A2
protein. CaP: prostate cancer, IS: immunoreactive score.
FIG. 4. Kaplan-Meier product-limit analysis of the length of bio-
chemical relapse-free survival among prostate cancer patients 
with low expression (IS=0 or 1) and high expression (IS=2 or 3) 
of S100A4 protein. CaP: prostate cancer, IS: immunoreactive score.
and decrease in S100A2 expression was observed in cancer 
specimens according to clinical stage and the pathologic 
grade (Gleason score) (p＜0.05) (Table 3, 4, Fig. 1, 2). The 
Spearman correlation between S100A2 and S100A4 was 
found to be - 0.55 (p＜0.001) based on mean that the total 
of every specimen.
3. Association of S100A2 and S100A4 with biochemical re-
lapse-free survival
Of the 67 patients with CaP, 10 (14.9%) had evidence of bio-
chemical relapse and 4 (5.9%) died from prostate cancer. 
The mean follow-up period in our study was 32.3 months. 
The length of biochemical relapse-free survival among the 
18 patients with immunoreactive scores of 2 or 3 (Group 2) 
for S100A2 was statistically longer than among the 49 pa-
tients with immunoreactive scores of 0 or 1 (Group 1) 
(log-rank, p=0.035) (Fig. 3). The length of biochemical re-
lapse-free survival among the 26 patients with an im-
munoreactive score of 0 or 1 (Group 3) for S100A4 was stat-
istically longer than among the 41 patients with an im-
munoreactive score of 2 or 3 (Group 4) for S100A4 (log-rank, 
p=0.021) (Fig. 4).
DISCUSSION
The S100 proteins are small acidic proteins (10-12 kDa) 
that are found exclusively in vertebrates [19]. With at least 
25 members of this protein family identified to date in hu-
mans, the S100 proteins constitute the largest subfamily 
of EF-hand proteins. Of these, 21 family members (S100A1 - 
S100A18, trichohyalin, filaggrin and repetin) have genes 
clustered at chromosome locus 1q21; other S100 proteins 
are found at chromosome loci 4p16 (S100P), 5q14 (S100Z), 
21q22 (S100B), and Xp22 (S100G). First identified by 
Moore in 1965, the S100 proteins exhibit 25-65% identity 
at the amino acid level and contain 2 EF-hand motifs 
flanked by conserved hydrophobic residues separated by 
a linker region [19,20]. The sequences of the linker region 
and the C-terminal extension are the most variable parts 
of the sequence among the S100 proteins. The S100 pro-
teins are hypothesized to participate in signal trans duction 
pathways that regulate cell cycle progression and differ-
entiation; however, the precise functions of these proteins 
are unknown.
  The S100A2 gene encodes a protein of 99 amino acids. The Korean J Urol 2010;51:456-462
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gene is located on chromosome 1q21, in a region that is fre-
quently rearranged in a number of human cancers [5,8]. 
Expression of S100A2 is regulated during the cell cycle, 
with its levels increasing as cells enter the S phase, and in-
duced by growth factors in the early G1 phase of the normal 
cell cycle [8]. Because S100A2 is believed to be regulated 
by the tumor-suppressor p53, induction of p53 activity by 
cell cycle arrest caused by DNA damage results in in-
creased S100A2 transcription [21,22]. The loss of S100A2 
expression is associated with the development and pro-
gression of some human cancers [9-14]. Recently, S100A2 
was proposed to be a class II tumor suppressor gene because 
of its loss of expression in a large number of tumors. This 
loss of expression is believed to influence the regulation of 
genes that are important for normal cell growth and differ-
entiation [12,23]. In our study, we observed decreased 
S100A2 expression in CaP. It is important to emphasize 
that we observed decreased S100A2 expression only in CaP 
and not in BPH (nonmalignant). 
  Another member of the S100 family of proteins is S100A4, 
which influences cell cycle progression and cell motility, 
and modulates intracellular adhesion and invasiveness 
[15,16]. Expression of the S100A4 gene has been linked to 
invasion and metastasis of cancer cells and is upregulated 
in a number of human cancers [16,24]. Amplification or 
overexpression of S100A4 in patients with breast cancer re-
flects increased metastatic potential of the cancer, which 
is prognostically significant and closely correlated with 
death [25]. S100A4 has been reported to be expressed in 
44% of foci of carcinoma within colon adenoma specimens 
and 94% of those of colon carcinoma specimens [26]. In our 
study, we observed high expression of S100A4 in invasive 
CaP. We also observed that decreased expression of 
S100A4 gene reduces the growth and proliferative poten-
tial of CaP. These results indicate that the S100A4 protein 
may be associated with proliferation, invasion, and meta-
stasis during the progression of CaP.
  During about 5 years of follow-up, 10 of 67 (14.9%) pa-
tients had a biochemical relapse based on PSA levels. We 
found that the length of biochemical relapse-free survival 
was longer in those patients with higher expression of 
S100A2 and shorter for those with higher expression of 
S100A4. This finding indicates that expression of S100A2 
and S100A4 is significantly associated with prognosis.
  Our study was limited by its retrospective design, the rel-
atively small number of patients, and the short length of 
follow-up. This makes it difficult to draw definitive con-
clusions. Because a single pathologist assessed the im-
munohistochemical staining of samples in a blinded fash-
ion, interobserver variance was not tested in this study.
CONCLUSIONS
We found an inverse relationship between expression of 
S100A2 and S100A4 protein in CaP and BPH. Reduced ex-
pression of S100A2 and increased expression of S100A4 in 
CaP was associated with clinical advancement and biologic 
aggressiveness of tumors. Hence, the simultaneous analy-
sis of S100A2 and S100A4 expression in prostate tissues 
may be a useful prognostic marker for CaP.
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